TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Options:
A: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
C: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: Pulmonary function Testing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Options:
A: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
B: Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma
Brief Summary: The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444


Options:
A: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
B: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
C: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone propionate
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Brief Summary: This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.


Options:
A: Arm Label: solifenacin succinate (VESIcare); Type: EXPERIMENTAL; Interventions: Drug: solifenacin succinate (VESIcare) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: solifenacin succinate (VESIcare); Assigned to Arm(s): solifenacin succinate (VESIcare) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin Succinate; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate
C: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic Fibrosis
Brief Summary: The purpose of this study is to test the safety and efficacy of the final commercial formulation of an antioxidant enriched multivitamin supplement in softgel capsule form (AquADEKs) in increasing the plasma levels of certain nutrients and antioxidants in individuals with cystic fibrosis.

Hypothesis: An oral antioxidant-rich multivitamin supplement (AquADEKs), which uses a Generally Regarded As Safe (GRAS) molecule to form micelle-like vehicles, will safely increase systemic levels of beta-carotene, coenzyme Q10, and gamma-tocopherol, decrease PIVKA-II levels, while maintaining levels of vitamins A and D in the normal range in persons with CF \> 10 years of age.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: KB001 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: KB001; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
D: Arm Label: Antioxidant-enriched multivitamin supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AquADEK | Intervention Type: DIETARY_SUPPLEMENT; Name: AquADEK; Assigned to Arm(s): Antioxidant-enriched multivitamin supplement

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Results of Open Mesh Versus Suture Repair in Treatment of Abdominal Wall (Multicentric, Prospective, Randomised, Internet-based, Clinical Trial)
Brief Summary: The purpose of this study is to:

1. compare the long term results of mesh versus suture repair in treatment of abdominal wall defects;
2. find the optimal location of implanted prosthesis, comparing the two most useful position of mesh in abdominal wall hernia surgery.


Options:
A: Arm Label: small hernias - suture repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: small hernias - mesh repair; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: large hernias - sublay mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Arm Label: large hernias - onlay mesh; Type: ACTIVE_COMPARATOR; Interventions: Procedure: abdominal wall reconstruction | Intervention Type: PROCEDURE; Name: abdominal wall reconstruction; Assigned to Arm(s): large hernias - onlay mesh, large hernias - sublay mesh, small hernias - mesh repair, small hernias - suture repair
B: Arm Label: fixation with Protack; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Protack | Arm Label: fixation with Securestrap; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Securestrap | Arm Label: fixation with Glubran; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic ventral herniotomy, Device: Glubran | Intervention Type: PROCEDURE; Name: laparoscopic ventral herniotomy; Assigned to Arm(s): fixation with Glubran, fixation with Protack, fixation with Securestrap | Intervention Type: DEVICE; Name: Protack; Assigned to Arm(s): fixation with Protack | Intervention Type: DEVICE; Name: Securestrap; Assigned to Arm(s): fixation with Securestrap | Intervention Type: DEVICE; Name: Glubran; Assigned to Arm(s): fixation with Glubran
C: Arm Label: 1; Type: OTHER; Interventions: Procedure: Open mesh repair of ventral incisional hernia, Procedure: Laparoscopic mesh repair of ventral incisional hernia | Intervention Type: PROCEDURE; Name: Open mesh repair of ventral incisional hernia; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Laparoscopic mesh repair of ventral incisional hernia; Assigned to Arm(s): 1
D: Intervention Type: PROCEDURE; Name: Retromuscular Mesh repair of midline incisional hernia; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Laparoscopic repair of midline incisional hernia; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment.
Brief Summary: The study will test the hypothesis that, in patients with knee pain due to osteoarthritis (OA) who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) but still have significant knee pain, duloxetine 60 to 120 milligrams (mg) daily for 10 weeks will provide additional reduction in pain.


Options:
A: Arm Label: Nortriptyline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nortriptyline Hydrochloride | Arm Label: Placebo (for nortriptyline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for nortriptyline) | Intervention Type: DRUG; Name: Nortriptyline Hydrochloride; Assigned to Arm(s): Nortriptyline | Intervention Type: DRUG; Name: Placebo (for nortriptyline); Assigned to Arm(s): Placebo (for nortriptyline)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Sugar pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment.
Brief Summary: The study will test the hypothesis that, in patients with knee pain due to osteoarthritis (OA) who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) but still have significant knee pain, duloxetine 60 to 120 milligrams (mg) daily for 10 weeks will provide additional reduction in pain.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 120 mg, Duloxetine 20 mg, Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder
Brief Summary: This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).


Options:
A: Arm Label: Ganaxolone; Type: EXPERIMENTAL; Interventions: Drug: Ganaxolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ganaxolone; Assigned to Arm(s): Ganaxolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GSK561679; Type: EXPERIMENTAL; Interventions: Drug: GSK561679 | Intervention Type: DRUG; Name: GSK561679; Assigned to Arm(s): GSK561679 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Prolonged Exposure Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Active Psychotherapy | Intervention Type: PROCEDURE; Name: Prolonged Exposure Therapy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Active Psychotherapy; Assigned to Arm(s): 2
D: Arm Label: Experimental ketamine group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Active control midazolam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Experimental ketamine group | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Active control midazolam group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer
Brief Summary: The three specific aims of this study are 1) to assess the impact of iron status on relative differences in absorption of heme and non-heme iron among pregnant women and non-pregnant women, 2) to assess the magnitude and the determinants of heme and non-heme iron transfer to the fetus over the last trimester of pregnancy, and 3) to characterize relationships between placental iron binding proteins with the enrichment of stable iron isotopes in the neonate at birth. The investigators hypothesize that there will be up regulation of heme and non-heme iron absorption and up regulation of placental iron transport proteins in response to low maternal iron stores.


Options:
A: N/A
B: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
C: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Daminaide 995 - SuppleFem Sprinkles; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Materna; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Women's Adherence to Women-only, Home-based and Traditional Cardiac Rehabilitation (Cardiac Rehabilitation for Her Heart Event Recovery [CR4HER])
Brief Summary: The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
B: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation

Answer: D